Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.

[1]  A. Fairlamb,et al.  Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar? , 2015, The Lancet.

[2]  S. Sundar,et al.  Antimony Resistant Leishmania donovani but Not Sensitive Ones Drives Greater Frequency of Potent T-Regulatory Cells upon Interaction with Human PBMCs: Role of IL-10 and TGF-β in Early Immune Response , 2014, PLoS neglected tropical diseases.

[3]  S. Croft,et al.  Modular Multiantigen T Cell Epitope–Enriched DNA Vaccine Against Human Leishmaniasis , 2014, Science Translational Medicine.

[4]  A. Fairlamb,et al.  Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis , 2013, Proceedings of the National Academy of Sciences.

[5]  S. Sundar,et al.  Miltefosine‐unresponsive Leishmania donovani has a greater ability than miltefosine‐responsive L. donovani to resist reactive oxygen species , 2013, The FEBS journal.

[6]  J. Beijnen,et al.  Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Syamal Roy,et al.  RFLPs of ITS, ITS1 and hsp70 amplicons and sequencing of ITS1 of recent clinical isolates of Kala-azar from India and Bangladesh confirms the association of L. tropica with the disease. , 2012, Acta tropica.

[8]  S. Sundar,et al.  Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis , 2012, PLoS neglected tropical diseases.

[9]  S. Müller,et al.  Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background , 2012, PLoS neglected tropical diseases.

[10]  M. Quail,et al.  Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. , 2011, Genome research.

[11]  D. Singh,et al.  Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani , 2011, Antimicrobial Agents and Chemotherapy.

[12]  S. Sundar,et al.  Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. , 2011, International journal for parasitology.

[13]  Syamal Roy,et al.  Restoration of IFNγR Subunit Assembly, IFNγ Signaling and Parasite Clearance in Leishmania donovani Infected Macrophages: Role of Membrane Cholesterol , 2011, PLoS pathogens.

[14]  S. Sundar,et al.  Genetic Heterogeneity in Clinical Isolates of Leishmania donovani from India , 2011, Journal of Clinical Microbiology.

[15]  Syamal Roy,et al.  Characterization of the recent clinical isolates of Indian Kala-azar patients by RAPD-PCR method , 2011, Journal of parasitic diseases : official organ of the Indian Society for Parasitology.

[16]  S. Sundar,et al.  Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[17]  G. Van der Auwera,et al.  Heat-shock protein 70 PCR-RFLP: a universal simple tool for Leishmania species discrimination in the New and Old World , 2010, Parasitology.

[18]  D. Lockwood,et al.  Treatment of Visceral Leishmaniasis , 2010, Journal of global infectious diseases.

[19]  Shyam Sundar,et al.  Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). , 2009, Acta tropica.

[20]  H. Ahmed,et al.  UNRESPONSIVENESS TO MILTEFOSINE IN VISCERAL LEISHMANIASIS (VL) - AN EXPERIENCE OF SEVEN CASES , 2008 .

[21]  R. Peeling,et al.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.

[22]  R. Kumar,et al.  Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools. , 2007, The American journal of tropical medicine and hygiene.

[23]  V. Yardley,et al.  Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? , 2007, Microbes and infection.

[24]  V. Yardley,et al.  Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[25]  Ashutosh,et al.  Molecular mechanisms of antimony resistance in Leishmania. , 2007, Journal of medical microbiology.

[26]  A. Fairlamb,et al.  Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.

[27]  S. Croft,et al.  Chemotherapy in the treatment and control of leishmaniasis. , 2006, Advances in parasitology.

[28]  S. Farajnia,et al.  Leishmania major: genetic heterogeneity of Iranian isolates by single-strand conformation polymorphism and sequence analysis of ribosomal DNA internal transcribed spacer. , 2006, Acta tropica.

[29]  Jean-Claude Dujardin,et al.  Risk factors in the spread of leishmaniases: towards integrated monitoring? , 2006, Trends in parasitology.

[30]  Edward R. T. Tiekink,et al.  Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine , 2005 .

[31]  S. Sundar,et al.  The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[32]  S. Sundar,et al.  Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models , 2005, Parasitology Research.

[33]  Yanbin Dong,et al.  Single-strand conformational polymorphism analysis: basic principles and routine practice. , 2005, Methods in molecular medicine.

[34]  Yanbin Dong,et al.  Single-strand conformational polymorphism analysis: basic principles and routine practice. , 2005, Methods in molecular medicine.

[35]  M. Miles,et al.  Leishmania donovani complex: genotyping with the ribosomal internal transcribed spacer and the mini-exon , 2004, Parasitology.

[36]  J. Alvar,et al.  Leishmania/HIV co-infections: epidemiology in Europe , 2003, Annals of tropical medicine and parasitology.

[37]  A. K. Chakraborti,et al.  Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? , 2003, Environmental health perspectives.

[38]  J. Marfurt,et al.  Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. , 2003, Diagnostic microbiology and infectious disease.

[39]  Shyam Sundar,et al.  Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.

[40]  S. Sundar.  Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[41]  G. Schönian,et al.  Molecular epidemiology and population genetics in Leishmania , 2001, Medical Microbiology and Immunology.

[42]  S. Sundar.  Treatment of visceral leishmaniasis , 2001, Medical Microbiology and Immunology.

[43]  L. Oskam,et al.  Genetic heterogeneity in the species Leishmania tropica revealed by different PCR-based methods. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[44]  L. Oskam,et al.  Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. , 2001, Experimental parasitology.

[45]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  G. Schönian,et al.  Genetic heterogeneity of ribosomal internal transcribed spacer in clinical samples of Leishmania donovani spotted on filter paper as revealed by single-strand conformation polymorphisms and sequencing. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[47]  F. Pratlong,et al.  Genetic variability within the species Leishmania aethiopica does not correlate with clinical variations of cutaneous leishmaniasis. , 2000, Molecular and biochemical parasitology.

[48]  S. Sundar,et al.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. , 1999, The Journal of infectious diseases.

[49]  R. Gasser,et al.  Mutation scanning methods for the analysis of parasite genes. , 1997, International journal for parasitology.

[50]  T. Singh,et al.  Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. , 1995, The American journal of tropical medicine and hygiene.

[51]  R. Kreutzer,et al.  Indian kala-azar caused by Leishmania tropica , 1995, The Lancet.

[52]  P. Vos,et al.  AFLP: a new technique for DNA fingerprinting. , 1995, Nucleic acids research.

[53]  M. Ouellette,et al.  High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. , 1994, Molecular and biochemical parasitology.

[54]  V. Sheffield,et al.  The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. , 1993, Genomics.

[55]  C. P. Thakur,et al.  Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. , 1992, Annals of tropical medicine and parasitology.

[56]  L. Schnur.  Control of the leishmaniases. Report of a WHO Expert Committee. , 1992, World Health Organization technical report series.

[57]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[58]  J. BOIX-BARRIOS.  [Treatment of visceral leishmaniasis]. , 1950, Revista espanola de pediatria.